Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06392672
Status:
COMPLETED
Last Update Posted:
2024-04-30
First Post:
2024-04-25
Brief Title:
Evaluation of the Effect of Drug-Related Problems in Pulmonary Embolism
Sponsor:
Bezmialem Vakif University
Organization:
Bezmialem Vakif University
Study Overview
Official Title:
Evaluation of the Effect of Management of Drug-Related Problems on Clinical Outcomes of Pulmonary Embolism Outpatients
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pulmonary embolism PE presents notable risks of morbidity and mortality underscoring the need for customized anticoagulant treatment There is a scarcity of research examining drug-related issues DRPs in PE This research endeavor seeks to assess how addressing DRPs affects the clinical outcomes of PE patients receiving outpatient care offering valuable insights to bolster patient safety measures
This study will conduct a randomized controlled trial on PE patients in Istanbul Turkey from January 15 2022 to January 15 2023 The intervention group IG will receive clinical pharmacist CP recommendations for DRPs while the control group CG will undergo observation only Evaluations will occur at 90- and 180-days post-discharge focusing on DRPs CP interventions and patient outcomes Data will be systematically recorded and analyzed adhering to ethical standards and employing the PCNE v91 classification system
This study will conduct a randomized controlled trial on PE patients in Istanbul Turkey from January 15 2022 to January 15 2023 The intervention group IG will receive clinical pharmacist CP recommendations for DRPs while the control group CG will undergo observation only Evaluations will occur at 90- and 180-days post-discharge focusing on DRPs CP interventions and patient outcomes Data will be systematically recorded and analyzed adhering to ethical standards and employing the PCNE v91 classification system
Detailed Description:
Pulmonary embolism PE involves the blockage of the pulmonary artery or one of its branches by materials like thrombus from elsewhere in the body This condition is linked to increased mortality and morbidity rates and if left untreated it can result in recurring episodes Additionally using anticoagulant therapy poses a significant risk of severe bleeding
Recent guidelines recommend customizing the duration of PE treatment based on the type of underlying risk factor distinguishing between transient and persistent factors Prolonged treatment without a persistent risk factor may heighten the risk of bleeding Hence selecting appropriate treatment options tailored to individual patient needs is crucial
The main goal of our study is to evaluate how managing drug-related problems DRPs in pulmonary embolism PE outpatients influences their clinical outcomes This research aims to provide valuable insights into the effectiveness of interventions targeting DRPs within the framework of PE management
Recent guidelines recommend customizing the duration of PE treatment based on the type of underlying risk factor distinguishing between transient and persistent factors Prolonged treatment without a persistent risk factor may heighten the risk of bleeding Hence selecting appropriate treatment options tailored to individual patient needs is crucial
The main goal of our study is to evaluate how managing drug-related problems DRPs in pulmonary embolism PE outpatients influences their clinical outcomes This research aims to provide valuable insights into the effectiveness of interventions targeting DRPs within the framework of PE management
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None